Atreca Presents Promising Findings From Lead Antibody Program At Society For Immunotherapy Of Cancer (SITC) Annual Meeting
- Based on Positive Data Demonstrating Tumor Targeting and Destruction In Vitro, Atreca’s Program Has Advanced to Studies in Preclinical In Vivo Models of Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today positive preclinical findings generated using the Company’s Immune Repertoire Capture® (IRC™) technology, presented at the SITC 2016 Annual Meeting, which is taking place in National Harbor, Maryland, November 9-13, 2016. In a poster titled, “Immune Profiling of an Elite Responder Following Checkpoint Inhibitor Therapy Reveals Functional Anti-Tumor Antibodies Within Expanded IgG Lineages,” a research team including scientists at Atreca and collaborators at a leading institution reported key research findings, including:
“Atreca is pioneering next-generation approaches to cancer immunotherapy based on our ability to elucidate the repertoire of cancer patient antibodies and T cell receptors (TCRs) contributing to positive outcomes”
- Atreca’s IRC™ technology generated diverse antibodies from the active immune response of an individual with Stage 4 melanoma who had experienced long-term non-progression of disease following cancer regimens including anti-CTLA4 immunotherapy. These antibodies were sequenced from the patient’s blood plasmablasts, activated B cells that play a critical role in immune responses.
- In in vitro assays, antibodies were shown to selectively bind tumor tissue but not normal tissue and to bind tumor types beyond the cancer type of the original patient.
- Select antibodies demonstrated in vitro tumor killing through antibody-dependent cellular cytotoxicity (ADCC).
“Atreca is pioneering next-generation approaches to cancer immunotherapy based on our ability to elucidate the repertoire of cancer patient antibodies and T cell receptors (TCRs) contributing to positive outcomes,” stated Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research. “In our presentation at SITC, we reported sequencing of over 2500 plasmablasts and identification of clonal antibody families from one exceptional cancer responder. By generating natively paired antibody heavy and light chain sequences, we were able to confirm the ability of a patient’s antibodies to target tumor cells and destroy them, including tumor types unrelated to that of the patient.”
“Atreca is advancing a pipeline of therapeutic candidates that can drive and focus the activity of immune responses in cancer immunotherapy, particularly those unleashed by checkpoint inhibitors and immune activators,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “We are thrilled to present data highlighting the power and productivity of our platform at one of the leading cancer immunotherapy conferences. Our lead program is rapidly advancing in preclinical in vivo studies, and we look forward to further progress of our additional programs across multiple indications.”
For more information on Atreca’s product portfolio, please visit http://www.atreca.com/therapeutics/.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Atreca is able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T-cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® (IRC™) technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.